Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;21(1):3-4.
doi: 10.1016/S1474-4422(21)00412-9.

2021 marks a new era for Alzheimer's therapeutics

Kejal Kantarci  1
Affiliations

2021 marks a new era for Alzheimer's therapeutics

Kejal Kantarci. Lancet Neurol. 2022 Jan.
No abstract available

PubMed Disclaimer

References

    1. US Food & Drug Administration FDA grants accelerated approval for Alzheimer's drug. June 7, 2021. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerat...
    1. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8:398–410. - PMC - PubMed
    1. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691–1704. - PubMed
    1. Novak P, Kovacech B, Katina S, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging. 2021;1:521–534. - PubMed
    1. Jack CR, Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–562. - PMC - PubMed

Publication types

Substances